inTest Corporation (NASDAQ: INTT) has gone down by 4.19% or $.19 to settle at $4.35 with a moderate volume of 132,815 shares. The stock traded today between $4.35 and $4.56 and has been trading between $1.30 to $4.65 in the past 52-week range with a market capitalization of $45 million.
inTEST Corporation is an independent designer, manufacturer and marketer of mechanical, thermal and electrical products that are used by semiconductor manufacturers in conjunction with automatic test equipment (ATE), in the testing of integrated circuits (ICs). The Company supplies its products worldwide to semiconductor manufacturers and semiconductor test subcontractors directly and through ATE manufacturers. It is organized in three segments: Mechanical Products, Thermal Products and Electrical Products.
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) has dropped 0.56% or one cent to settle at $1.76 with a moderate volume of 49,505 shares compared to its three-month volume of 261,819 shares. The stock has been trading today between $1.72 and $1.81 and has been trading between $.98 and $2.25 in the last 52 weeks with a market capitalization of $59.32 million.
Threshold Pharmaceuticals, Inc (Threshold) is a biotechnology company focused on the discovery and development of drugs targeting the microenvironment of solid tumors as treatments for patients living with cancer. Its product candidates are designed to focus on the hypoxic microenvironment of tumors either by selective toxin activation in the case of its hypoxia activated prodrug (HAP) program, including TH-302, or utilizing the consequences of increased uptake of glucose in cancer cells relative to most normal cells. The Company's product candidate 2-deoxyglucose (2DG) and glufosfamide share certain structural characteristics with glucose but act instead as chemotherapeutic toxins when taken up by a cell.
MER Telemanagement Solutions (NASDAQ: MTSL) has gained 3.24% or six cents to settle at $1.91 with a volume of 11,224 shares compared to its average three-month volume of 85,302 shares. The stock has been trading between $1.80 and $1.91 and has been trading between one dollar and four dollar range in the past 52 weeks with a market capitalization of $8.5 million.
Mer Telemanagement Solutions Ltd. is a provider of solutions for telecommunications expense management (TEM), used by enterprises, and billing solutions, used by information and telecommunication service providers. The Company's TEM solutions assist enterprises and organizations to make smarter choices with their telecommunications spending at each stage of the service lifecycle, including allocation of cost, proactive budget control, fraud detection, processing of payments and spending forecasting.
PositiveID Corp. (NASDAQ: PSID) has lost 1.64% or one cent to settle at $.54 a share with a moderate volume of 56,075 shares compared to its average three-month volume of 293,262. Today company traded between $.53 and $.55 and has been trading between $.50 and $1.99 in the past 52 weeks with a market capitalization of $16.35 million.
PositiveID Corporation is engaged in developing, marketing and selling radio frequency identification (RFID), systems used for the identification of people in the healthcare market. The Company is focusing on providing health and security identification tools to protect consumers and businesses, operating in two segments: HealthID and ID Security. The Company's HealthID segment is focused on the development of the glucose-sensing microchip, in conjunction with Receptors LLC (Receptors). Its HealthID segment also includes the VeriMed system, which uses an implantable passive RFID microchip (the VeriChip) that is used in patient identification applications.
Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) has gone down 4.53% or $.24 to settle at $5.06 with a moderate volume of hundred 30,456 shares traded compared to its average three-month volume of 145,627 shares. Today the stock ranged between $5.00 and $5.31 and has been trading between $1.99 and $5.68 in the past 52-weeks with a market capitalization of $295 million.
Achillion Pharmaceuticals, Inc. (Achillion) is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for infectious diseases. Within the anti-infective market, the Company focuses on the development of antivirals for the treatment of chronic hepatitis C and the development of antibacterials for the treatment of resistant bacterial infections. As of December 31, 2009, Achillion focused on developing three Hepatitis C virus (HCV) drug candidates: ACH-1625, a protease inhibitor for the treatment of chronic hepatitis C in phase Ib clinical testing; ACH-1095, a NS4A antagonist also for the treatment of chronic hepatitis C, in late stage preclinical testing, and ACH-2684, a high-potency protease inhibitor in preclinical testing.
OTCPicks.com is not a registered investment advisers or broker/dealer. OTCPicks.com makes no recommendation that the purchase of securities of companies profiled in this website is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market their securities, investing in such securities is highly speculative and carries a high degree of risk. Always do you own homework before investing in any stock.
Forward-Looking Statement: This press release includes "forward-looking statements" within the meaning of the federal securities laws, commonly identified by such terms as "believes," "looking ahead," "anticipates," "estimates" and other terms with similar meaning. Although the Company believes that the assumptions upon which its forward-looking statements are based are reasonable, it can give no assurance that these assumptions will prove to be correct. Important factors that could cause actual results to differ materially from the Company's projections and expectations are disclosed in the Company's filings with the Securities and Exchange Commission. All forward-looking statements in this press release are expressly qualified by such cautionary statements and by reference to the underlying assumptions.
Disclosure: OTCpicks.com has not been compensated for any stocks listed in this stock news report
